Some of these scum are still active in the world.

http://www.deepcapture.com/wp-content/uploads/story-of-dendreon.pdf

On September 26, 2005, Cramer announced to his television audience the sad news (punctuated by

funny sound effects – a clown horn, a crashing airplane) that Provenge, an experimental treatment for

prostate cancer, had flopped. Thousands of end-stage patients had been pinning their hopes on

Provenge, but according to Cramer the treatment had just been rejected by the Food & Drug

Administration. It would never go to market.

This seemed odd, because Dendreon (NASDAQ: DNDN), the company developing Provenge, had not yet

submitted an application for FDA approval. As everybody in the biotech investment community knew, in

fact, Dendreon had only recently completed Phase 3 clinical trials and probably would not face scrutiny

from an FDA advisory panel for at least another year.